The Indian pharmaceutical market posted a 12-13.5 percent growth rate in the second quarter, driven by strong demand for chronic medication. While this domestic rise is offsetting weaker US sales, investors are paying attention to potential profit margin pressure from rising input and freight costs.
The Indian pharmaceutical industry is seeing a period of strong domestic growth, with market revenue increasing by 12 to 13.5 percent in recent months. This performance marks a notable recovery in the second quarter of fiscal year 2027, driven largely by sustained demand for chronic therapies. For many Indian drug manufacturers, this local strength has provided a vital buffer against the ongoing slowdown in international markets.
Chronic Demand Fuels Local Growth
Growth is being supported by a steady rise in the consumption of medicines for long-term health conditions, specifically cardiology, diabetes, and oncology. Unlike past periods where growth often came from price hikes, the current trend shows a meaningful increase in the actual volume of medicine sold. Companies such as Sun Pharmaceutical Industries, Zydus Lifesciences, Glenmark Pharmaceuticals, and Torrent Pharmaceuticals are among those seeing these trends in their portfolios.
US Market Pressure and Profit Margins
While the domestic market shows strength, the US business—a major contributor to revenue for many listed players—continues to face hurdles. Sales projections for finished dosage drugs in the US remain subdued due to persistent pricing pressure and a lack of new high-value generic product launches. This has forced companies to balance their business strategies. Furthermore, investors are looking closely at profitability. Despite higher revenue, companies may face a 150 to 200 basis point contraction in profit margins. This pressure is largely coming from rising expenses related to raw materials, energy, and freight, alongside continued investments in research and development.
Looking ahead, the sector's performance will depend on the balance between domestic volume growth and the ability to control costs. Regulatory and trade policy developments, including potential US trade actions, remain factors that the industry is navigating. Investors may track how companies manage their expense ratios and whether domestic volume trends can continue to sustain overall earnings momentum as the sector enters the second half of the financial year.